Allison Humphries's Publications

About Allison Humphries's Publications

Senior Research Fellow, Respiratory Programme
  • Operations Lead, Academic Project Operations

  • The feasibility of analyzing food consumption combinations from overweight and obese participants of weight loss clinical trials.

    Date published:

  • The feasibility of analysing food consumption combinations from overweight and obese participants of weight loss clinical trials

    Date published:

  • Development of an At-Risk Assessment Approach to Dietary Data Quality in a Food-Based Clinical Trial

    Studies in Health Technology and Informatics Date published:

  • Feasibility of a community-based interdisciplinary lifestyle intervention trial on weight loss (the HealthTrack study)

    Nutrition & Dietetics Date published:

  • Interdisciplinary lifestyle intervention for weight management in a community population (HealthTrack study): Study design and baseline sample characteristics

    Contemporary Clinical Trials Date published:

  • Measuring Data Quality Through a Source Data Verification Audit in a Clinical Research Setting

    Studies in Health Technology and Informatics Date published:

  • HIV Lipodystrophy in Participants Randomised to Lopinavir/Ritonavir (LPV/r) +2-3 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (N(t)RTI) or LPV/r + Raltegravir as Second-Line Antiretroviral Therapy

    PLOS One Date published:

  • Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy

    AIDS Date published:

  • Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study

    The Lancet Date published:

  • Bone mineral density in HIV participants randomized to raltegravir plus lopinavir/ritonavir compared to standard second-line therapy.

    AIDS Date published:

  • Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard fi rst-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study.

    LANCET Date published:

  • The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV

    AIDS Date published:

  • The influence of HLA supertype on thymidine analogue-associated with low peripheral fat in HIV

    AIDS Date published:

  • Predictors of Limb Fat Gain in HIV Positive Patients Following a Change to Tenofovir-Emtricitabine or Abacavir-Lamivudine

    PLOS One Date published:

  • Abacavir does not affect circulating levels of inflammatory or coagulopathic biomarkers in suppressed HIV: a randomized clinical trial

    AIDS Date published:

  • Reply to Landmann and Soonawala

    Clinical Infectious Diseases Date published: